Mirum Pharmaceuticals (MIRM) Operating Expenses (2019 - 2026)

Mirum Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $949.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 648.89% year-over-year to $949.3 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 199.85% increase from a year earlier, with the FY2025 full-year figure at $543.4 million, up 28.02% from the prior year.
• Operating Expenses improved to $949.3 million in Q1 2026 per MIRM's latest filing, from $153.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $949.3 million in Q1 2026 and bottomed at $45.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $102.1 million (2024), against an average of $142.4 million.
• Across the five-year window, Operating Expenses dropped 4.17% in 2022 and surged 648.89% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $62.1 million in 2022, then jumped by 64.56% to $102.1 million in 2023, then climbed by 21.05% to $123.6 million in 2024, then gained by 24.15% to $153.5 million in 2025, then jumped by 518.47% to $949.3 million in 2026.
• Per Business Quant, the three latest MIRM Operating Expenses figures stand at $949.3 million (Q1 2026), $153.5 million (Q4 2025), and $130.4 million (Q3 2025).